Explore All Access
Check if your research matches the topics covered in Chinese Clinical Oncology?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Chinese Clinical Oncology : Impact Factor & More
eISSN: 2304-3873pISSN: 2304-3865
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Chinese Clinical Oncology Key Metrics
CiteScore 
4.2
SNIP
1.03
Chinese Clinical Oncology Journal Specifications
| Overview | |
| Publisher | AME PUBLISHING COMPANY |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Chinese Clinical Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Chinese Clinical Oncology
Triplet regimen with camrelizumab plus apatinib in combination with hepatic artery infusion chemotherapy (HAIC): a new treatment paradigm for select patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma?
- 1 Oct 2024
- Chinese clinical oncology
Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.
- 1 Oct 2024
- Chinese clinical oncology
Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma.
- 1 Oct 2024
- Chinese clinical oncology
Current status, evolution, and future perspectives in robotic platform systems for prostate cancer treatment: a narrative review.
- 1 Oct 2024
- Chinese clinical oncology
A case report of successful combined intra-arterial immunotherapy and cytokine genetic therapy treatment in a patient with recurrent glioblastoma.
- 1 Oct 2024
- Chinese clinical oncology
Evidence from resected early-stage non-small cell lung cancer with EGFR mutation: a literature review.
- 1 Oct 2024
- Chinese clinical oncology
Triplet regimen with camrelizumab plus apatinib in combination with hepatic artery infusion chemotherapy (HAIC): a new treatment paradigm for select patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma?
- 1 Oct 2024
- Chinese clinical oncology
Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.
- 1 Oct 2024
- Chinese clinical oncology
Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma.
- 1 Oct 2024
- Chinese clinical oncology
Current status, evolution, and future perspectives in robotic platform systems for prostate cancer treatment: a narrative review.
- 1 Oct 2024
- Chinese clinical oncology
A case report of successful combined intra-arterial immunotherapy and cytokine genetic therapy treatment in a patient with recurrent glioblastoma.
- 1 Oct 2024
- Chinese clinical oncology
Evidence from resected early-stage non-small cell lung cancer with EGFR mutation: a literature review.
- 1 Oct 2024
- Chinese clinical oncology
FAQs on Chinese Clinical Oncology
How long has Chinese Clinical Oncology been actively publishing? 
Chinese Clinical Oncology has been in operation since 2012 till date.
What is the publishing frequency of Chinese Clinical Oncology?
Chinese Clinical Oncology published with a Quarterly frequency.
How many articles did Chinese Clinical Oncology publish last year?
In 2024, Chinese Clinical Oncology publsihed 63 articles.
What is the eISSN & pISSN for Chinese Clinical Oncology?
For Chinese Clinical Oncology, eISSN is 2304-3873 and pISSN is 2304-3865.
What is Citescore for Chinese Clinical Oncology?
Citescore for Chinese Clinical Oncology is 4.2.
What is SNIP score for Chinese Clinical Oncology?
SNIP score for Chinese Clinical Oncology is 1.03.
Who is the publisher of Chinese Clinical Oncology?
AME PUBLISHING COMPANY is the publisher of Chinese Clinical Oncology.
